HOME >> MEDICINE >> NEWS
International study highlights underuse of reperfusion therapy for heart-attack patients

N.B. Please note that if you are outside North America the embargo time for Lancet Press Material is 0001 hours UK Time Friday 1st February 2002.

Up to a third of patients with a severe heart attack may not be receiving reperfusion therapy, despite the well-known benefits of this treatment strategy, conclude authors of an international study in this weeks issue of THE LANCET.

The benefits of reperfusion therapy- the use of fibrinolytic agents and/or coronary angioplasty to restore coronary artery bloodflow -for patients with acute coronary syndromes have been established, but there is variation in the type of reperfusion given and in decisions about which patients are eligible for such therapy. Kim Eagle from the University of Michigan Medical Center, USA, and colleagues assessed current practices in relation to reperfusion therapy in patients with a specific heart-attack profile called ST-segment-elevation myocardial infarction using data from the multinational, prospective Global Registry of Acute Coronary Events (GRACE). This registry includes data for patients with acute coronary syndromes from 94 hospitals in 14 countries.

The investigators assessed data of the first 9251 patients enrolled in GRACE; of these, 1763 presented within 12 hours of symptom onset with ST-segment-elevation myocardial infarction, 30% of whom did not receive reperfusion therapy. Elderly patients (75 years and older), those presenting without chest pain, and those with a history of diabetes, congestive heart failure, myocardial infarction, or coronary bypass surgery were less likely to receive reperfusion therapy. The rate of primary percutaneous coronary intervention was highest in the USA (17%) and lowest in Australia, New Zealand, and Canada (1%). The rate at sites with a catheterisation laboratory was 19%.

Kim Eagle comments: A substantial proportion of patients who are eligible for reperfusion therapy still do not receive this treatment.
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7611-4076
Lancet
31-Jan-2002


Page: 1 2

Related medicine news :

1. International breast cancer prevention study launches in the United States and Canada
2. National Academies advisory: May 2 Symposium on International Science Policy
3. Awards & fellowships at the International & American Association for Dental Research General Session
4. Lectures, keynoters, symposia highlight International Dental Research meeting
5. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
6. International gathering of experts to share retinoblastoma breakthroughs
7. International trial of two microbicides begins
8. International gathering at UH examines top computer code
9. International trial finds benefits of breast MRI in women at high risk
10. International study provides culture-by-culture clues to family violence and abuse
11. St. Jude scientist wins International Society of Experimental Hematology award

Post Your Comments:
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... Interrupting blood supply to an arm or a leg before ... surgery, according to a new study. "During heart ... heart to be able to operate on it. After some ... to produce energy because it doesn,t get oxygen. When we ... as an arm or a leg, the body prepares for ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Not getting the ... ulcerative colitis, a new study suggests. Those who ... eight hours per night may be more prone to ... intestines, researchers report. The study authors concluded that duration ... considered among patients with inflammatory bowel diseases. "Both ...
(Date:10/25/2014)... A large influx of international aid is needed, and ... thousands of deaths from the widening Ebola crisis, a ... a specially designed mathematical model, the researchers looked at ... densely populated county of hard-hit Liberia -- Montserrado County, ... researchers said that if international aid isn,t delivered to ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research ... and Drug Administration (FDA) has given the company permission ... AS2-1 in patients > 3 months of age with ... be placed in one of five treatment groups based ... received prior treatment for DIPG. The primary study endpoint ...
(Date:10/22/2014)... 22, 2014  Cephasonics, a technology-innovation leader with a ... cQUB™-1 (cQuest Ultrasound Box™-1), the first product in a ... manufactured by Cephasonics for purchase by companies to rebrand ... will be showcasing the cQUB-1 for the first time ... Chongqing, China from October 23 ...
(Date:10/22/2014)... 22, 2014 Antigen Discovery Inc. (ADi), a ... , announced the receipt of a National Institutes of ... from the National Institute of Dental and Craniofacial Research (NIDCR). ... a Pan-HIV Protein Microarray Chip, which will contain every ... and aid in the development of safe and effective ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
Cached News: